EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications

Zhihui Zhou, Qi Niu, Xiyuan Yu, Chaoyong Yang, Zhi Zhu iD

Chemistry – A European Journal · 2026-09-24 · 32 (36)

DOI: 10.1002/chem.71255 ↗

At a glance

Übersichtsarbeit in Chemistry – A European Journal, published on 2026-09-24. Written by Zhihui Zhou and 4 co-authors. Institution: The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, Department of Chemical Biology, College of Chemistry and Chemical Engineering, …. Major MEDLINE topics: Lysosomes. Cited 1 times so far (Crossref); 178 references. Funded by: National Key R&D Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Targeted protein degradation (TPD) has emerged as a transformative therapeutic strategy, but most existing approaches are restricted to intracellular proteins. Lysosome‐targeting chimeras (LYTACs) expand the scope of TPD by enabling the selective degradation of extracellular and membrane‐associated proteins through the endosomal–lysosomal pathway. This review provides a comprehensive overview of LYTAC technology, focusing on its molecular architecture and mechanism of action. We systematically examine the evolution of LYTACs from two key design dimensions: (1) the diversity of protein‐of‐interest (POI) binders, including antibodies, aptamers, small molecules, peptides, and DNA scaffolds; and (2) the expanding repertoire of lysosomal targeting receptors (LTRs), from classical receptors, cation‐independent mannose‐6‐phosphate receptor (CI‐M6PR) and asialoglycoprotein receptor (ASGPR), to emerging tissue‐restricted, multifunctional, and programmable entry routes. Finally, we discuss strategies to enhance degradation efficiency, pharmacokinetics/pharmacodynamics (PK/PD) profiles, and address key challenges for clinical translation, offering a framework for the rational design of next‐generation LYTAC therapeutics.

Subjects

MeSH terms (MEDLINE)

LysosomesHumansReceptor, IGF Type 2AnimalsProteolysis

Author keywords

endocytosis mechanismlysosome‐targeting chimerasmolecular architecturetargeted protein degradationtherapeutic application

Substances

Receptor, IGF Type 2

Authors and institutions

  • The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, China.
  • Institute of Molecular Medicine, State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID profiles: Zhi Zhu

Funding

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Cite

APA

Zhou, Z., Niu, Q., Yu, X., Yang, C., & Zhu, Z. (2026). Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications. Chemistry – A European Journal. https://doi.org/10.1002/chem.71255

Vancouver

Zhou Z, Niu Q, Yu X, Yang C, Zhu Z. Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications. Chemistry – A European Journal. 2026. doi:10.1002/chem.71255

BibTeX
@article{Zhou2026,
  author = {Zhou, Zhihui and Niu, Qi and Yu, Xiyuan and Yang, Chaoyong and Zhu, Zhi},
  title = {Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications},
  journal = {Chemistry – A European Journal},
  year = {2026},
  doi = {10.1002/chem.71255}
}
Start for free →